Movers and SHAKERS
Onconova Therapeutics Inc. (ONTX)
New Publication Describes Rigosertib's Mechanism For Improving Checkpoint Inhibitor Responses
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
New Rigosertib Study Shows Mechanism Of Action A study published in the medical journal Molecular Cancer detailed how rigosertib's action through the RAS pathway could improve the response to checkpoint inhibitors. Rigosertib is currently in a Phase 1 clinical trial in combination with the PD-1 inhibitor Opdivo (nivolumab) to improve response rates in lung cancer.
Turning "Cold" Tumors "Hot" Drugs in the checkpoint inhibitor category block the mechanism that allows cancer cells to avoid recognition by the immune system. Response rates for checkpoint inhibitors vary from about 10% to 40% depending on the tumor. The new publication supports observations in prior rigosertib trials by demonstrating increases in immune cell populations and responses ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.